Vistagen Therapeutics Inc VTGN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Vistagen Selects GATC Health to Apply Predictive AI Across Lead Clinical-Stage Drug Development Programs
-
SRX Global Provides Shareholders with Update on Liquidation of Two Portfolio Investments and Adds an Investment in Onconetix (Nasdaq: ONCO)
-
Vistagen Reports Positive Findings Supporting Fasedienol’s Potential in Very Severe Social Anxiety Disorder
-
Vistagen Announces Preliminary Positive Data from Open-Label Extension Portion of PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
-
Vistagen to Present at Psych Congress 2026
-
Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update
-
Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder
Trading Information
- Previous Close Price
- $0.17
- Day Range
- $0.17–0.19
- 52-Week Range
- $0.17–5.14
- Bid/Ask
- $0.17 / $0.19
- Shares Outstanding
- 44.38M
- Market Cap
- $8.18M
- Volume/Avg
- 1M / 12M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.74
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 41
- Website
- https://www.vistagen.com
Valuation
|
Metric
|
VTGN
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.30 |
Price/Sales | 2.74 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
VTGN
|
|---|---|
Quick Ratio | 2.84 |
Current Ratio | 3.07 |
Interest Coverage | — |
Quick Ratio
VTGN
Profitability
|
Metric
|
VTGN
|
|---|---|
Return on Assets (Normalized) | −107.62% |
Return on Equity (Normalized) | −137.60% |
Return on Invested Capital (Normalized) | −136.69% |
Return on Assets
VTGN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|c?N$hmg | LOCK|!zDW? | $135B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|VXVD?Q? | LOCK|&&bD? | $101B | |||
| Moderna Inc
MRNA
| LOCK|X@gtVB@ | LOCK|YCQ | $91B | |||
| argenx SE ADR
ARGX
| LOCK|dn<<q!> | LOCK|BdL | $56B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|&d!X%p | LOCK|WP | $41B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|CfXdg!DH | LOCK|nCFhG | $30B | |||
| Incyte Corp
INCY
| LOCK|y$%FgLv | LOCK|t@ | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|LxQ!Tt | LOCK|gD | $22B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|Sg^<#gK | LOCK|^Tdk | $21B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|XRD!DLg | LOCK|p>r | $15B |
United States